On May 14, 2025, Pennsylvania State Sen. Tim Kearney and State Rep. Lisa Borowski introduced legislation addressing private equity and corporate interests in healthcare. Pennsylvania Gov. Josh Shapiro is touting the companion…
more
/ Business Organizations, Constitutional Law, Health, Insurance, Mergers & Acquisitions
In a May 15, 2025, opinion, Judge Dabney Friedrich of the US District Court for the District of Columbia denied drugmakers’ motions for summary judgment against the US Department of Health and Human Services and the Health…
more
/ Administrative Law, Health, Science, Computers, & Technology
On May 22, 2025, the FDA approved Bio-Thera Solutions and Hikma Pharmaceuticals’ ustekinumab biosimilar, STARJEMZA® (ustekinumab-hmny) injection, referencing Janssen’s STELARA® (ustekinumab) injection…
more
/ Health, Science, Computers, & Technology
We have written about the opportunities for the managers of private funds, such as private equity, real estate, venture, and infrastructure managers, to increase the investor base for the funds they manage (funds) to include…
more
/ Commercial Law & Contracts, Finance & Banking, Securities Law
In the lower middle market — typically deals between $10 million and $100 million — the letter of intent (LOI) serves as a pivotal document that sets the tone for the transaction, shapes the seller’s expectations, and determines…
more
/ Commercial Law & Contracts, Mergers & Acquisitions, Taxation
Maryland has enacted a law that establishes a financial-services oversight regime for earned wage access services, also known as on-demand pay services, which allow workers to access earned but unpaid income before payday. The…
more
/ Consumer Protection, Finance & Banking, Labor & Employment Law
On May 22, 2025, the House of Representatives narrowly passed the "One Big Beautiful Bill Act," a budget reconciliation package setting forth President Trump’s domestic agenda, including a sweeping 10-year federal moratorium on…
more
/ Conflict of Laws, Constitutional Law, Science, Computers, & Technology
On 8 May 2025, the European Commission (“the Commission”) launched two public consultations as part of its comprehensive review of the guidelines for horizontal and non-horizontal mergers…
more
/ Antitrust & Trade Regulation, Business Organizations, International Law & Trade, Mergers & Acquisitions
On May 20, 2025, the New York Court of Appeals agreed to hear constitutional challenges to one aspect of New York’s Foreclosure Abuse Prevention Act (FAPA)…
more
/ Constitutional Law, Finance & Banking, Real Estate - Residential
On May 19, Novavax, Inc. (“Novavax”) announced that FDA approved its Biologics License Application (“BLA”) for Nuvaxovid™ for active immunization against COVID-19 in adults 65 years and older and individuals 12 through 64 years…
more
/ Health, Science, Computers, & Technology
As of May 27, 2025, Meta (Facebook and Instagram) will start using some of the personal data of European users to train its artificial intelligence (AI) systems, including tools such as Meta AI and Llama language models…
more
/ Communications & Media Law, Privacy, Science, Computers, & Technology
At-the-market (ATM) offering programs continue to provide public real estate investment trusts (REITs) and other issuers an efficient means of raising capital over time by allowing a listed company to tap into the existing…
more
/ Finance & Banking, Real Estate - Commercial, Securities Law
On May 13, 2025, Biogen Inc. and Biogen MA Inc. (“Biogen”) filed a Complaint for Declaratory Judgment and Permanent Injunctive Relief against Neurimmune Holding AG and Neurimmune SubOne AG (“Neurimmune”) in the U.S. District…
more
/ Commercial Law & Contracts, Health, Intellectual Property
On May 14, 2025, HyClone Laboratories, LLC (“HyClone”) filed a Motion to Quash in the U.S. District Court for the District of Utah, seeking to quash Amgen Inc.’s (“Amgen”) subpoena to HyClone issued in Amgen’s denosumab BPCIA…
more
/ Intellectual Property, Science, Computers, & Technology
On May 15, 2025, a jury returned a verdict finding Amgen Inc. (“Amgen”) liable for antitrust violations and awarding Regeneron Pharmaceuticals, Inc. (“Regeneron”) over $400 million in damages…
more
/ Antitrust & Trade Regulation, Business Torts, Science, Computers, & Technology
